Live Breaking News & Updates on Effrx Pharmaceuticals For Alkindi

REPUBLIC OF SOUTH AFRICA OR
JAPAN. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
 
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF THE LAW OF
ENGLAND AND
WALES BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION. ....

United States , District Of Columbia , United Kingdom , South Africa , Northern Ireland , City Of , New Zealand , Republic Of South Africa , Great Britain , Europe Alkindi , Foster Mitchell , Chiesi Farmaceutici , Emma Earl , Sam Williams , Medison Pharma , John Goddard , Freddy Crossley , Martin Whitaker , Richard Bungay , Panmure Gordon , Simon Conway , Panmure Gordons , Rupert Dearden , Effrx Pharmaceuticals For Alkindi , Company To Panmure Gordon , Consilient Health For The Nordic ,